Assertio Holdings Inc
ASRT
Company Profile
Business description
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Contact
100 South Saunders Road
Suite 300
Lake ForestIL60045
USAT: +1 224 419-7106
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
30
Stocks News & Analysis
stocks
Why I dislike dividend stocks
If you need income then buying dividend stocks makes perfect sense. But if you don’t then it makes little sense because it’s likely to limit building real wealth. Here’s what you should do instead.
stocks
Chart of the Week: Ramsay Health Care margins to rebound
Charts from our latest stock pitch for Ramsay Health Care show a clear path to improved profitability.
stocks
BlackRock earnings: Market gains and inflows drive AUM and revenue to record highs
We plan to raise our fair value estimate of BlackRock stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,375.90 | 19.70 | 0.21% |
| CAC 40 | 8,154.66 | 77.66 | 0.96% |
| DAX 40 | 24,196.80 | 15.43 | 0.06% |
| Dow JONES (US) | 46,253.31 | 17.15 | -0.04% |
| FTSE 100 | 9,398.27 | 26.48 | -0.28% |
| HKSE | 25,888.51 | 22.09 | -0.09% |
| NASDAQ | 22,670.08 | 148.38 | 0.66% |
| Nikkei 225 | 48,277.74 | 605.07 | 1.27% |
| NZX 50 Index | 13,389.10 | 81.70 | 0.61% |
| S&P 500 | 6,671.06 | 0.00 | 0.00% |
| S&P/ASX 200 | 9,068.40 | 18.20 | 0.20% |
| SSE Composite Index | 3,916.23 | 4.02 | 0.10% |